share_log

Johnson & Johnson | 10-Q: Q2 2024 Earnings Report

Johnson & Johnson | 10-Q: Q2 2024 Earnings Report

强生 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/26 04:04

Moomoo AI 已提取核心信息

Johnson & Johnson reported Q2 2024 worldwide sales of $22.4 billion, representing a 4.3% increase year-over-year, with operational growth of 6.6% offset by a negative currency impact of 2.3%. The Innovative Medicine segment grew 5.5% to $14.5 billion, driven by strong performance of key brands including DARZALEX, TREMFYA and ERLEADA. MedTech segment sales increased 2.2% to $8.0 billion.The company's earnings before tax decreased to $5.7 billion from $6.3 billion in Q2 2023, with margin declining to 25.6% from 29.3%. This was primarily impacted by acquisition and integration costs related to the $13.1 billion Shockwave Medical acquisition completed in May 2024, as well as a $0.4 billion loss from the Kenvue share exchange transaction.Looking ahead, J&J is pursuing multiple pathways to resolve talc claims, including a proposed $6.5 billion settlement plan. The company maintained strong liquidity with $24.9 billion in cash and equivalents at quarter-end. Management continues to invest in growth initiatives while advancing its pharmaceutical and medical device portfolios through strategic acquisitions and R&D investments.
Johnson & Johnson reported Q2 2024 worldwide sales of $22.4 billion, representing a 4.3% increase year-over-year, with operational growth of 6.6% offset by a negative currency impact of 2.3%. The Innovative Medicine segment grew 5.5% to $14.5 billion, driven by strong performance of key brands including DARZALEX, TREMFYA and ERLEADA. MedTech segment sales increased 2.2% to $8.0 billion.The company's earnings before tax decreased to $5.7 billion from $6.3 billion in Q2 2023, with margin declining to 25.6% from 29.3%. This was primarily impacted by acquisition and integration costs related to the $13.1 billion Shockwave Medical acquisition completed in May 2024, as well as a $0.4 billion loss from the Kenvue share exchange transaction.Looking ahead, J&J is pursuing multiple pathways to resolve talc claims, including a proposed $6.5 billion settlement plan. The company maintained strong liquidity with $24.9 billion in cash and equivalents at quarter-end. Management continues to invest in growth initiatives while advancing its pharmaceutical and medical device portfolios through strategic acquisitions and R&D investments.
强生报告2024年第二季度全球销售额为224亿美金，同比增长4.3%，其中运营增长为6.6%，但受到2.3%的负货币影响。创新药物部门增长5.5%至145亿美金，主要受到DARZALEX、TREMFYA和ERLEADA等主要品牌表现强劲的推动。医疗技术部门销售额增长2.2%至80亿美金。公司的税前盈余从2023年第二季度的63亿美金下降至57亿美金，利润率从29.3%下降至25.6%。这主要受到与2024年5月完成的131亿美金ShockWave Medical收购相关的收购和整合成本的影响，以及Kenvue股份交易造成的4亿美金损失。展望未来，强生正在寻求多种途径解决滑石粉索赔问题，包括提议的65亿美金和解计划。公司在季度末保持强劲的流动性，现金及现金等价物达249亿美金。管理层继续投资于增长计划，同时通过战略收购和研发投资推动其药品和器械组合的发展。
强生报告2024年第二季度全球销售额为224亿美金，同比增长4.3%，其中运营增长为6.6%，但受到2.3%的负货币影响。创新药物部门增长5.5%至145亿美金，主要受到DARZALEX、TREMFYA和ERLEADA等主要品牌表现强劲的推动。医疗技术部门销售额增长2.2%至80亿美金。公司的税前盈余从2023年第二季度的63亿美金下降至57亿美金，利润率从29.3%下降至25.6%。这主要受到与2024年5月完成的131亿美金ShockWave Medical收购相关的收购和整合成本的影响，以及Kenvue股份交易造成的4亿美金损失。展望未来，强生正在寻求多种途径解决滑石粉索赔问题，包括提议的65亿美金和解计划。公司在季度末保持强劲的流动性，现金及现金等价物达249亿美金。管理层继续投资于增长计划，同时通过战略收购和研发投资推动其药品和器械组合的发展。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿玛琳
    AMRN
    -- 0.612
    赛诺菲安万特
    SNY
    -- 54.500
    艾伯维公司
    ABBV
    -- 192.870
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。